Literature DB >> 6233248

Norfloxacin: activity against urinary tract pathogens and factors influencing the emergence of resistance.

D Greenwood, M Osman, J Goodwin, W A Cowlishaw, R Slack.   

Abstract

The activity of norfloxacin was investigated in vitro in conventional minimum inhibitory concentration tests, by continuous turbidimetry and in a mechanical model simulating the hydrokinetic conditions that exist in the treatment of bacterial cystitis. The high activity of norfloxacin against virtually all bacterial pathogens isolated from infected urine was confirmed. However, in urine agar (pH 6 X 5) and in DST agar adjusted to pH 5 X 5, the activity was substantially reduced. Turbidimetric experiments indicated that increases in resistance to norfloxacin could be induced easily by sequential subculture, but results obtained in the bladder model, where conditions of exposure more closely resemble those that exist during the treatment of infection, suggest that such resistance is unlikely to arise commonly during treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6233248     DOI: 10.1093/jac/13.4.315

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  First clinical isolate of highly fluoroquinolone-resistant Escherichia coli in Scandanavia.

Authors:  M Jonsson; M Walder; A Forsgren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

2.  In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.

Authors:  J M Stamm; C W Hanson; D T Chu; R Bailer; C Vojtko; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

3.  Studies on the emergence of resistance to lomefloxacin in vitro.

Authors:  M Kanematsu; D Greenwood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

4.  Susceptibility of Campylobacter species to nalidixic acid, enoxacin, and other DNA gyrase inhibitors.

Authors:  D E Taylor; L K Ng; H Lior
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

Review 5.  Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; D M Richards
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

6.  Norfloxacin penetration into human renal and prostatic tissues.

Authors:  M G Bergeron; M Thabet; R Roy; C Lessard; P Foucault
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

7.  Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.

Authors:  D Gargallo; M Moros; R Coll; M Esteve; J Parés; M A Xicota; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

8.  Antibacterial activity of ciprofloxacin in conventional tests and in a model of bacterial cystitis.

Authors:  D Greenwood; S Baxter; A Cowlishaw; A Eley; G J Slater
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

9.  Comparative activity of ofloxacin and seven other antimicrobials against urea-splitting microorganisms.

Authors:  A Torres; R Fernández-Roblas; B Méndez; F Soriano
Journal:  Infection       Date:  1986       Impact factor: 3.553

10.  Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections.

Authors:  C Peña; J M Albareda; R Pallares; M Pujol; F Tubau; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.